Last reviewed · How we verify
NB004 tablets
At a glance
| Generic name | NB004 tablets |
|---|---|
| Also known as | Sotorasib |
| Sponsor | Ningbo Newbay Technology Development Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NB004 tablets CI brief — competitive landscape report
- NB004 tablets updates RSS · CI watch RSS
- Ningbo Newbay Technology Development Co., Ltd portfolio CI